Supplementary Tables from Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

Supplemental Tables: Supplementary Table S1A. Estimated tumor volume of MDA-MB-231 xenografts treated with entinostat, ATRA, and doxorubicin as single and combined therapies. Supplementary Table S1B. Comparison of the estimated tumor volume of MDA-MB-231 xenografts treated with entinostat, ATRA, and doxorubicin as single and combined therapies. Supplementary Table S2A. Estimated tumor volume of SUM-159 xenografts treated with entinostat, ATRA, and doxorubicin as single and combined therapy. Supplementary Table S2B. Comparison of the estimated tumor volume of SUM-159 xenografts treated with entinostat, ATRA, and doxorubicin as single and combined therapy. Supplementary Table S3A. Estimated tumor volume of MDA-MB-231 xenografts treated with entinostat, ATRA, and carboplatin as single and combined therapy. Supplementary Table S3B. Comparison of the estimated tumor volume of MDA-MB-231 xenografts treated with entinostat, ATRA, and carboplatin as single and combined therapies. Supplementary Table S4A. Estimated tumor volume of SUM-159 xenografts treated with entinostat, ATRA, and carboplatin as single and combined therapy. Supplementary Table S4B. Comparison of the estimated tumor volume of SUM-159 xenografts treated with entinostat, ATRA, and carboplatin as single and combined therapy. Supplementary Table S5. Necrosis scores in mouse xenografts. Supplementary Table S6. EAD treatment shows reduced tumor incidence at limiting dilution. Supplementary Table S7. Characteristics of primary patient samples.